Davita Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Davita Inc. has submitted its 2023 annual report (10-K), detailing its financial performance and business operations for the year ended December 31, 2023.</b>

AI Summary

DAVITA INC. (DVA) filed a Annual Report (10-K) with the SEC on February 14, 2024. Davita Inc. filed its 2023 Form 10-K on February 14, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 2000 16th Street, Denver, CO 80202. Davita Inc. was formerly known as Davita Healthcare Partners Inc. and Total Renal Care Holdings Inc. The filing includes financial data for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking DAVITA INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Davita's financial health, operational results, and strategic positioning for investors and stakeholders. The detailed financial statements and risk factors disclosed in this report are crucial for understanding the company's performance and future outlook in the healthcare services sector.

Risk Assessment

Risk Level: medium — DAVITA INC. shows moderate risk based on this filing. The company operates in the highly regulated healthcare industry, facing potential risks from changes in government reimbursement policies and healthcare laws, which could materially impact its financial results.

Analyst Insight

Investors should review Davita's detailed financial statements and risk factors in the 10-K to assess its performance and potential challenges in the dialysis and healthcare services market.

Key Numbers

• 20231231 — Fiscal Year End (Conformed period of report)
• 20240214 — Filing Date (Filed as of date)
• 8090 — Standard Industrial Classification (SIC code for Services-Misc Health & Allied Services, NEC)
• DE — State of Incorporation (State where Davita Inc. is incorporated)

Key Players & Entities

• DAVITA INC. (company) — Filer name
• 2000 16TH STREET (address) — Business address
• DENVER (location) — Business address city
• CO (location) — Business address state
• 80202 (postal_code) — Business address zip
• DAVITA HEALTHCARE PARTNERS INC. (company) — Former company name
• TOTAL RENAL CARE HOLDINGS INC (company) — Former company name
• 20231231 (date) — Conformed period of report

FAQ

Industry Context

Davita Inc. operates within the healthcare services industry, specifically focusing on kidney dialysis and related services.

Regulatory Implications

The healthcare industry is subject to extensive regulation by government bodies such as the Centers for Medicare & Medicaid Services (CMS), impacting reimbursement rates and operational standards.

What Investors Should Do

1. Review Davita's detailed financial statements for the fiscal year ended December 31, 2023.
2. Analyze the risk factors section to understand potential challenges and uncertainties facing the company.
3. Compare Davita's 2023 performance against previous years and industry benchmarks.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-02-14: Filing Date — Date the 10-K was officially filed with the SEC.

Year-Over-Year Comparison

This filing is the annual 10-K report for the fiscal year 2023, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.001 — nge on which registered: Common Stock, $0.001 par value DVA New York Stock Exchange
• $1.2 — and subsequent activity in Congress, a $1.2 trillion sequester (across-the-board sp

Filing Documents

• dva-20231231.htm (10-K) — 2982KB
• dva-123123ex211.htm (EX-21.1) — 383KB
• dva-123123ex231.htm (EX-23.1) — 2KB
• dva-123123ex31110xk.htm (EX-31.1) — 9KB
• dva-123123ex31210xk.htm (EX-31.2) — 9KB
• dva-123123ex32110xk.htm (EX-32.1) — 6KB
• dva-123123ex32210xk.htm (EX-32.2) — 5KB
• a971davitadodd-frankcompen.htm (EX-97.1) — 29KB
• dva-20231231_g1.gif (GRAPHIC) — 50KB
• dva-20231231_g2.jpg (GRAPHIC) — 40KB
• dva-20231231_g3.jpg (GRAPHIC) — 809KB
• 0000927066-24-000013.txt (&nbsp;) — 17702KB
• dva-20231231.xsd (EX-101.SCH) — 100KB
• dva-20231231_cal.xml (EX-101.CAL) — 134KB
• dva-20231231_def.xml (EX-101.DEF) — 544KB
• dva-20231231_lab.xml (EX-101.LAB) — 1341KB
• dva-20231231_pre.xml (EX-101.PRE) — 883KB
• dva-20231231_htm.xml (XML) — 2306KB

Risk Factors

Item 1A. Risk Factors 26

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 53

Cybersecurity

Item 1C. Cybersecurity 53

Properties

Item 2. Properties 56

Legal Proceedings

Item 3. Legal Proceedings 56

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 56 PART II.

Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 57

Reserved

Item 6. Reserved 57

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 58

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 77

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 78

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 78

Controls and Procedures

Item 9A. Controls and Procedures 78

Other Information

Item 9B. Other Information 78

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 78 PART III.

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 79

Executive Compensation

Item 11. Executive Compensation 79

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 79

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 80

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 80 PART IV.

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 81

Form 10-K Summary

Item 16. Form 10-K Summary 81 Exhibit Index 1 of 4

Signatures

Signatures S-1 PART I

Business

Item 1. Business Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com , as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at http://www.sec.gov where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report. Overview of DaVita Inc. DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. We are one of the largest providers of kidney care services in the U.S. and have been a leader in clinical quality and innovation for more than 20 years. We care for our patients at every stage and setting along their kidney health journey – including earlier diagnosis and prevention, supporting the transplant process, helping with end of life and ensuring they are supported at home, in our dialysis centers, in the hospital and/or skilled nursing facilities and at the end of life. We are committed to bold, patient-centric care models, implementing the latest technologies and advancing integrated care offerings. In our unwavering pursuit of a healthier tomorrow, we have established a value-based culture with a philosophy of caring that is focused on both our patients and teammates. This culture and philosophy fuel our continuous drive toward achieving our mission to be the provider, partner and employer of choice. There are five stages of chronic kidney disease (CKD). These stages are generally b

View Full Filing

View this 10-K filing on SEC EDGAR